Alpha 2.0
Login Register
» Authors » G N Hortobagyi

G N Hortobagyi

Explore the profile of G N Hortobagyi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 426
Citations 8342
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
A U Buzdar
G R Blumenschein
R L Theriault
F A Holmes
V Valero
H Y Yap
T L Smith
G Fraschini
S E Singletary
D Frye
Published In
Cancer
Ann Oncol
J Clin Oncol
Semin Oncol
Cancer Treat Rep
Affiliations
Soon will be listed here.
Recent Articles
1.
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
Hortobagyi G, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, et al.
Ann Oncol . 2024 Oct; 36(2):149-157. PMID: 39442617
Background: NATALEE assessed efficacy and tolerability of 3 years of adjuvant ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) compared with an NSAI alone in a broad population of patients with...
2.
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022)...
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al.
Ann Oncol . 2022 Dec; 34(7):630. PMID: 36564285
No abstract available.
3.
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, et al.
Ann Oncol . 2021 Dec; 33(3):321-329. PMID: 34954044
Background: In the primary analysis of the HER2CLIMB trial, tucatinib added to trastuzumab and capecitabine significantly improved overall survival (OS) and progression-free survival (PFS) in patients with human epidermal growth...
4.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, et al.
Ann Oncol . 2019 Aug; 30(11):1842. PMID: 31407010
No abstract available.
5.
Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, et al.
Ann Oncol . 2018 May; 29(7):1541-1547. PMID: 29718092
Background: The phase III MONALEESA-2 study demonstrated significantly prolonged progression-free survival (PFS) and a manageable toxicity profile for first-line ribociclib plus letrozole versus placebo plus letrozole in patients with hormone...
6.
Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)
Sharma P, Barlow W, Godwin A, Pathak H, Isakova K, Williams D, et al.
Ann Oncol . 2018 Jan; 29(3):654-660. PMID: 29293876
Background: Homologous recombination deficiency (HRD)-causing alterations have been reported in triple-negative breast cancer (TNBC). We hypothesized that TNBCs with HRD alterations might be more sensitive to anthracycline plus cyclophosphamide-based chemotherapy...
7.
Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity
Reddy S, Barcenas C, Sinha A, Hsu L, Moulder S, Tripathy D, et al.
Br J Cancer . 2017 Dec; 118(1):17-23. PMID: 29235566
Background: We counsel our triple-negative breast cancer (TNBC) patients that the risk of recurrence is highest in the first 5 years after diagnosis. However, there are limited data with extended...
8.
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
Yamaguchi H, Du Y, Nakai K, Ding M, Chang S, Hsu J, et al.
Oncogene . 2017 Sep; 37(2):208-217. PMID: 28925391
Inhibitors against poly (ADP-ribose) polymerase (PARP) are promising targeted agents currently used to treat BRCA-mutant ovarian cancer and are in clinical trials for other cancer types, including BRCA-mutant breast cancer....
9.
Clinicopathological and surgical factors associated with long-term survival in patients with HER2-positive metastatic breast cancer
Harano K, Lei X, Gonzalez-Angulo A, Murthy R, Valero V, Mittendorf E, et al.
Breast Cancer Res Treat . 2016 Aug; 159(2):367-74. PMID: 27522517
Trastuzumab-based treatment has dramatically improved the outcomes of HER2-positive (HER2+) metastatic breast cancer (MBC) patients, with some patients achieving prolonged survival times. In this study, we aim to identify factors...
10.
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
Nahleh Z, Barlow W, Hayes D, Schott A, Gralow J, Sikov W, et al.
Breast Cancer Res Treat . 2016 Jul; 158(3):485-95. PMID: 27393622
SWOG S0800, a randomized open-label Phase II clinical trial, compared the combination of weekly nab-paclitaxel and bevacizumab followed by dose-dense doxorubicin and cyclophosphamide (AC) with nab-paclitaxel followed or preceded by...